Stock data
| Market cap. | US$9.9m |
| Last close | US$1.60 |
| High / Low (52 weeks) | US$1.9 / US$1.2 |
| Stock market listing | US |
| Forecast net debt (US$m) | 5.1 |
| Forecast gearing ratio (%) | 176 |
| Team | Healthcare |
| Sector | Pharmaceutical & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (8.6) | 11.9 | 15.9 |
| Relative * | (9.9) | 7.6 | 1.3 |
* % Relative to local index
Other companies in sector Show
Company news
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 7.2 | (4.5) | (4.9) | (33.82) | N/A | N/A |
| 2017A | 7.5 | (4.6) | (4.9) | (145.96) | N/A | N/A |
| 2018E | 8.8 | (5.8) | (6.7) | (98.15) | N/A | N/A |
| 2019E | 9.5 | (6.8) | (8.5) | (126.66) | N/A | N/A |
Last updated on 14/06/2018
Latest research
Third cohort ready to go
Update | Pharmaceutical & healthcare | 06/06/2018
Moving forward in Parkinsons and TBI
Outlook | Pharmaceutical & healthcare | 14/05/2018
Interim Parkinson's data
Update | Pharmaceutical & healthcare | 03/01/2018
Green light for second cohort
Update | Pharmaceutical & healthcare | 24/05/2017
Dosing of first cohort complete
Update | Pharmaceutical & healthcare | 27/04/2017
Phase I progressing
Update | Pharmaceutical & healthcare | 14/12/2016
First patient dosed in Phase I trial
Update | Pharmaceutical & healthcare | 02/08/2016
Seeking a better treatment for Parkinson's
Initiation | Pharmaceutical & healthcare | 16/05/2016
Investment summary
International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson’s disease (PD), and recently completed dosing of the first patient in their third cohort (a total of 9 so far). The company recently reported positive interim clinical data from the first cohort of patients in the trial. The company is also preparing to initiate a Phase II trial in traumatic brain injury in the coming months. With its hpSC technology, ISCO has created 15 stem cell lines, each of which is a different HLA type. From this, it creates different cell types such as liver cells, neural cells and three-dimensional eye structures.
Last updated on 29/06/2018
Industry outlook
ISCO’s technology platform is based on human parthenogenetic stem cells (hpSCs). Parthenogenetic stem cells are created from unfertilized human eggs (oocytes) chemically activated to make the cells pluripotent. As hpSCs express fewer parental histocompatibility antigens, they reduce the risk of immune rejection.
Last updated on 29/06/2018
Key management
| Andrey Semechkin, CEO and Co-Chairman |
| Donald Wright, Co-Chairman |
| Jennifer Stephens, Acting CFO |
| Russell Kern, Executive Vice President, CSO |
Company address
| 5950 Priestly Drive Carlsbad CA 92008 United States +1 760 940 6383 View website |